Phase II Multicenter, Double-Blind, Randomized Trial Comparing Anastrozole (ZD1033, Arimidex™)-Placebo to the Combination Anastrozole-ZD1839 (Gefitinib, IRESSA™) in Postmenopausal Patients With Estrogen Receptor (ER) and/or Progesterone Receptor (PgR) Metastatic Breast Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Time to progression
Iressa Medical Science Director, MD
Study Director
AstraZeneca
United States: Food and Drug Administration
1839US/0713
NCT00077025
January 2004
January 2014
Name | Location |
---|---|
Research Site | Anaheim, California |
Research Site | Boca Raton, Florida |
Research Site | Baton Rouge, Louisiana |
Research Site | Bangor, Maine |
Research Site | Baltimore, Maryland |
Research Site | Branson, Missouri |
Research Site | Grand Island, Nebraska |
Research Site | Las Vegas, Nevada |
Research Site | Belleville, New Jersey |
Research Site | Albuquerque, New Mexico |
Research Site | Albany, New York |
Research Site | Akron, Ohio |
Research Site | Allentown, Pennsylvania |
Research Site | Aberdeen, South Dakota |
Research Site | Abilene, Texas |